New insights into antibody levels against SARS-CoV-2 for healthcare personnel vaccinated with tozinameran (Comirnaty)Article Published on 2022-11-032022-11-15 Journal: PLoS ONE [Category] SARS, 진단, [키워드] activated addition addressed administration Alto Andújar antibody booster dose COVID-19 determine Dilution Elecsy Evolution exhibited Germany Guadalquivir healthcare personnel Healthcare professional humoral IgG in vitro infected patients material Neutralizing antibodies New non-infected pandemic platform Roche SARS-CoV-2 SARS-CoV-2 vaccine second dose serum sample Spike protein subject Thermo Fisher Scientific titer total antibody vaccination Vaccine Volunteer volunteers [DOI] 10.1371/journal.pone.0276968 PMC 바로가기
Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assaysArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 진단, [키워드] Abbott Accuracy antibodies antibody Antibody Response Antibody titer Architect BAU BNT162b2 ChAdOx1-S collected comparable correlation COVID-19 DiaSorin effective Elecsy elicited Genscript greater IgG immune response Immunoglobulin indicated individual International LIAISON Moderna mRNA-1273 naïve Neutralizing antibody titer Oxford-AstraZeneca Pfizer/BioNTech plasma protective immunity Quantitative Quantitative serological assays ranged regression analysis response Roche SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination sensitivity seroconverted serological serological response significantly higher specificity Standard tested the WHO unit Vaccine Vaccines virus neutralization assays WHO WHO international standard. World Health Organization [DOI] 10.1016/j.jcv.2022.105292 PMC 바로가기
Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 InfectionArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% confidence interval acute respiratory syndrome adjusted anti-SARS-CoV-2 IgG antibody assist association baseline Cohort cohort study conducted coronavirus Coverage COVID COVID-19 demonstrated disease risk England fire Flow Follow-up hospital IgG Immunity immunoassay immunoassays incidence rate individual Infection investigated Laboratory laboratory assays Lateral Lateral flow device lateral flow device. lateral flow immunoassay Lateral flow test LFIA LFIAs management microbiologically natural infection pandemic participant point-of-care test Poisson regression model Police service Population screening positive predicted prospective cohort study Protective Rapid Rapid test rapid test cassette recruitment Research Result risk risk factor Roche SARS-CoV-2 SARS-CoV-2 disease SARS-CoV-2 IgG SARS-COV-2 infection specificity subsequent Surescreen susceptibility symptomatic SARS-CoV-2 infection Test threshold United Kingdom unvaccinated populations Vaccine was tested [DOI] 10.1128/spectrum.02468-22 PMC 바로가기
Concordance of SARS-CoV-2 Antibody Results during a Period of Low PrevalenceArticle Published on 2022-10-262022-11-15 Journal: mSphere [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval Abbott acute respiratory syndrome Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG Antigen antigens Architect assays CDC collected combinations Concentration Concordance contributed coronavirus coronavirus disease COVID-19 Elecsy ELISA enzyme-linked immunosorbent evaluate False positivity first test Frequency IgG IgG antibodies immunoassay immunoassays Immunoglobulin individual investigated low prevalence nucleocapsid nucleocapsid protein pandemic participant Participants performed Period positive positive result Prevalence produced proportion quantified Research Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibody sequential test sera serological test seropositive specimen Spike protein spike protein. subset Support target tested the SARS-CoV-2 The United States Vaccine vaccine availability [DOI] 10.1128/msphere.00257-22 PMC 바로가기
Effectiveness of COVID-19 vaccination in healthcare workers in Shiga Prefecture, JapanArticle Published on 2022-10-212022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, [키워드] Abbott analyzed antibody Cell cells Cellular immune response cellular immunity conducted coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccinations Delta effective evaluated HCW HCWs health condition healthcare worker Hospitalization humoral induce Japan Poor questionnaire repeated required Roche SARS-CoV-2 SARS-COV-2 infection serological seropositive Standard deviation vaccination Vaccine Wuhan-1 [DOI] 10.1038/s41598-022-22682-3 PMC 바로가기
Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assaysArticle Published on 2022-10-012022-11-15 Journal: Journal of Clinical Virology [Category] COVID19(2023년), SARS, 진단, [키워드] Abbott Abbott SARS-CoV-2 IgG acute respiratory syndrome addition antibody antibody assay Antibody concentrations assays binding antibody unit coefficient comparable Concentration Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) Coronavirus-2 correlated correlation epidemiological purposes geometric indicated material Patient Pearson Quantitative Quantitative SARS-CoV-2 antibody assay ranged Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein sera Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Siemen Siemens Spike protein The diagnostic sensitivity the SARS-CoV-2 the WHO was determined WHO [DOI] 10.1016/j.jcv.2022.105269 PMC 바로가기
Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessmentArticle Published on 2022-09-152022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, 치료제, [키워드] anti-N antibody anti-S anti-S antibody Anti-SARS-CoV-2 S antiviral therapy can be used Cancer patients comparable correlated correlation COVID-19 Critical Elecsys® Anti-SARS-CoV-2 S evaluate expected Follow-up group Immune status immunoassay immunosuppressed patients in both groups linear Mild moderate Neutralization antibody Neutralization assay Neutralizing activity neutralizing antibody onset of symptom Patient patients patients with COVID-19 performance positive predict produced Proteins Roche SARS-CoV-2 neutralizing antibody serum serum sample significantly higher vaccine response Virus neutralization [DOI] 10.1371/journal.pone.0274181 PMC 바로가기
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational studyArticle Published on 2022-09-022022-10-06 Journal: Lancet Reg Health Eur [Category] 진단, [키워드] Adverse adverse events analysed AZD1222 Biogen Bristol Clinical data courses COVID-19 Deterioration effective fatigue Frequency Gender Germany headache Health impairment injection long-lasting longitudinal men Merck Serono Multiple multiple sclerosis Mylan Novartis occurred offer opposite Pain participated Patient reaction real-world data registry reported resulting Roche Sanofi SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine sclerosis severe COVID-19 disease Society Sociodemographic stratified Symptoms Tolerability United Kingdom vaccination Vaccination reaction Vaccination reaction. Vaccine women worsened [DOI] 10.1016/j.lanepe.2022.100502 PMC 바로가기 [Article Type] Article
Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid AntibodiesArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] Abbott Accuracy acute respiratory syndrome adjusted Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 immune response antibodies antibody Antibody concentrations Antibody detection Architect cohorts commercial immunoassay conducted convalescent individual coronavirus coronavirus disease COVID-19 cumulative dependent on Detection limit Elecsy ELISA enzyme-linked immunosorbent evaluated Follow-up Health care worker heterogenous highest IgG immune responses immunoassay immunoassays incidence individual Infection longitudinal lowest nucleocapsid protein Patient Reinfection response Roche SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 infections selected serological serological kinetics serum serum antibody Surveillance tested the SARS-CoV-2 threshold unique waning antibody. [DOI] 10.1128/spectrum.00986-22 PMC 바로가기
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA ThresholdsArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody assay standardization assays authorization can be used CCP clinical trials Clinical use Cohort collected comparable Concordance consequence convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma criteria Cutoff cutoff value Donor drug Emergency Emergency use authorization EUA Expanded Access Program FDA FDA EUA FIVE food high-titer CCP high-titer convalescent plasma highlight hospitalized patients identification identify immunosuppressed patients indicate Limited lowest monoclonal antibody multiple serological assay Pandemics Pathogens positive precluded provided ranged reduce released Roche SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant serologic serologic assay serological Serological assay serological assays serology Serology. serum sample significantly Standardization therapeutic therapeutic option therapy threshold Treatment [DOI] 10.1128/spectrum.01154-22 PMC 바로가기